1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in

Shitara, K.; Ben‐Aharon, Irit; Rojas, C.; Eyzaguirre, D.A. Acosta; Hubert, Ayala; Moya, H. Araya; Cohen, Deirdre Jill; Bai, L-Y.; Ghiringhelli, F.; Wyrwicz, L.; Janjigian, Y. Y.; Tabernero, J.; Cutsem, E. Van; Qin, Shu Kui; Xu, Jieting; Wang, A.; Miller, Mary Gwen; Shih, Chung; Bhagia, Pooja; Weber, P.E. Yanez

doi:10.1016/j.annonc.2022.07.1341

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No grade 5 and no grade ⩾3 immune-mediated AEs or infusion reactions occurred. 70 In conclusion, angiogenesis is crucial in cancer development and progression. Ramucirumab is the principal agent with antiangiogenetic activity currently used in GEA; however, several trials with other antiangiogenic are ongoing in this field, especially in combination with immuneoncological agents.…”

Section: Therapeutic Advances In Medical Oncologymentioning

confidence: 99%

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Petrillo¹,

Smyth

Laarhoven

2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.

show abstract

Section: Therapeutic Advances In Medical Oncologymentioning

confidence: 99%

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Petrillo¹,

Smyth

Laarhoven

2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

show abstract

“…These results suggest robust potential synergies for such combined treatments for AGC. The results of the safety run-in phase (part 1) of LEAP015, (a two-part, phase III study of safety and efficacy of lenvatinib + pembro + chemotherapy), yielded a high preliminary ORR of 73% and DCR, 93% [ 50 ].…”

Section: Anti-pd-1 Antibody Combined With Multikinase Inhibitorsmentioning

confidence: 99%

Recent Advances in Immunotherapy and Molecular Targeted Therapy for Gastric Cancer

Yoshinami¹,

Shoji²

2023

Future Sci. OA

View full text Add to dashboard Cite

Our increasing understanding of the molecular biological characteristics of cancer and of cancer genomics is facilitating the development of immunotherapy and molecular targeted drugs for gastric cancer. After the approval of immune checkpoint inhibitors (ICIs) for melanoma in 2010, many different cancers have been shown to respond to such treatments. Thus, the anti-PD-1 antibody nivolumab was reported to prolong survival in 2017, and ICIs have become the mainstay of treatment development. Many clinical trials of combination therapies with cytotoxic agents and molecular-targeted agents, as well as combinations of immunotherapeutic agents acting via different mechanisms, are currently underway for each treatment line. As a result, further improvements in therapeutic outcomes for gastric cancer are anticipated in the near future.

show abstract

State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care

Balmaceda,

Petrillo,

Krishnan

et al. 2024

Am Soc Clin Oncol Educ Book

View full text Add to dashboard Cite

Gastroesophageal cancers (GECs) represent a significant clinical challenge. For early resectable GEC, the integration of immune checkpoint inhibitors into the perioperative chemotherapy and chemoradiation treatment paradigms are being explored and showing promising results. Frontline management of metastatic GEC is exploring the role of targeted therapies beyond PD-1 inhibitors, including anti–human epidermal growth factor receptor 2 agents, Claudin 18.2 inhibitors, and FGFR2 inhibitors, which have shown considerable efficacy in recent trials. Looking ahead, ongoing trials and emerging technologies such as bispecific antibodies, antibody-drug conjugates, and adoptive cell therapies like chimeric antigen receptor T cells are expected to define the future of GEC management. These advancements signify a paradigm shift toward personalized and immunotherapy-based approaches, offering the potential for improved outcomes and reduced toxicity for patients with GEC.

show abstract

1223P First-line lenvatinib (Len) + pembrolizumab (Pembro) + chemotherapy (Chemo) vs chemo in advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015 safety run-in

Cited by 4 publications

References 0 publications

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Recent Advances in Immunotherapy and Molecular Targeted Therapy for Gastric Cancer

State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care

Contact Info

Product

Resources

About